Onyx continues slide, despite positive physician feedback at ASH
This article was originally published in Scrip
Executive Summary
Shares of Onyx Pharmaceuticals continued on the downward path for the second day on 13 December, despite revealing updated positive data for its next-generation proteasome inhibitor carfilzomib at the annual meeting of the American Society of Hematology (ASH) in San Diego.